Drug Profile
Avibactam/ceftazidime - Allergan/Pfizer
Alternative Names: AVE 1330/ceftazidime; AVE 1330A/ceftazidime; Avibactam/ceftazidime pentahydrate; AVYCAZ; CAZ 104; CAZ-AVI; Ceftazidime pentahydrate/avibactam; Ceftazidime/AVE 1330; Ceftazidime/AVE 1330A; Ceftazidime/NXL 104; NXL 104/ceftazidime; PF-06947386; ZAVICEFTA; ZaviceftaLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Novexel
- Developer AbbVie; Allergan; AstraZeneca; Cerexa; Novexel; Pfizer
- Class Amides; Antibacterials; Cephalosporins; Heterocyclic bicyclo compounds; Small molecules; Sulfates
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Nosocomial-pneumonia(In adolescents, In children, In infants) in Netherlands (IV, Infusion)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Ventilator-associated-pneumonia(In adolescents, In children, In infants) in China (IV, Infusion)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Ventilator-associated-pneumonia(In adolescents, In children, In infants) in Estonia (IV, Infusion)